Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 107175
Author(s) Frey, C; Bonert, A; Kratzsch, T; Rexroth, G; Rösch, W; Müller-Spahn, F; Maurer, K; Müller, W E; Eckert, A
Author(s) at UniBasel Eckert, Anne
Year 2006
Title Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease
Journal Journal of neural transmission
Volume 113
Number 11
Pages / Article-Number 1753-61
Keywords apoptosis, lymphocyte, caspase-3, Alzheimer patients, amyloid-beta, CD95
Abstract

The presumption to suffer from Alzheimer's disease (AD) accelerates with aging. One important risk factor seems to be the isoform epsilon 4 of the apolipoprotein E gene (Apo epsilon 4), which increases the risk to develop AD at an earlier age. Furthermore, convincing evidence is provided that apoptotic cell death mechanisms play an important role in neuronal cell death in AD. In the present study, we investigated whether abnormalities in apoptosis and caspase-3 activity can be found at the level of lymphocytes and a T cell subtype, CD4 T cells, from AD patients compared to aged sex- and ApoE genotype-matched non-demented controls. Under different experimental conditions (at baseline or after in vitro incubation in the presence of proapoptotic stimuli) increased levels of apoptosis and enhanced caspase-3 activity were detected in lymphocytes from AD patients. This difference was most pronounced in the CD4(+) T cell subtype. Notably, we found a significant increase of apoptotic cells and caspase-3 activity in lymphocytes from AD patients bearing one or two alleles of the ApoE4 compared to non-E4 carriers. Again, these effects were strongest in CD4(+) T cells. Circulating amyloid-beta (A beta) levels did not differ between AD patients bearing ApoE4 and non-ApoE4 and age-matched controls. Therefore, it is likely that circulating A beta is not responsible for the observed effects, which might rather reflect an ongoing systemic response in AD, e.g. an increase in CD95 expression.

Publisher Springer
ISSN/ISBN 0300-9564
edoc-URL http://edoc.unibas.ch/dok/A5253461
Full Text on edoc No
Digital Object Identifier DOI 10.1007/s00702-006-0481-y
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/16736246
ISI-Number WOS:000241611700016
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.542 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/04/2024